A rock-painting contest in Las Vegas. A fashion show in New York. A 7,000-meter race around the Washington Monument that’ll coincide with a similar #Racefor7 event in Bengaluru and Mumbai, India. From Athens to Atlanta, from San Diego to Sydney, people across the globe will mark World Rare Disease…
News
Eloctate use in immune tolerance induction (ITI) therapy shows promise in high-risk patients with severe hemophilia A and inhibitors treated for the first time, Bioverativ announced. The results support a potential benefit for some patients who tried and failed ITI with other factors. The study, “Recombinant factor VIII…
The Oklahoma Medical Research Foundation (OMRF) and Shanghai RAAS Blood Products are working together on the development of new hemophilia and traumatic bleeding therapies. This is the first time OMRF has collaborated with a Chinese blood products manufacturer. In 2017, Shanghai RAAS was 25th on Forbes’ “Growth Champions”…
Shire Korea recently received approval from South Korea’s Ministry of Food and Drug Safety for Adynovate (BAX 855), a long-lasting factor VIII gene recombinant therapy for hemophilia A. Adynovate is an injectable form of Shire’s Advate, which is Korea’s most commonly used treatment for the blood disorder. Shire Korea…
Researchers at Emory University School of Medicine have developed a small-scale model system to study bleeding and clotting of wounds. The miniature model also accurately reproduces the alterations observed in hemophilia A patients. Their work, “A microengineered vascularized bleeding model that integrates the principal components of hemostasis”, was published in…
David Curtis Glebe, a retired 64-year-old public prosecutor now living in Millsboro, Delaware, knows he’s lucky to be alive. In mid-2013, while in Arizona, Glebe was diagnosed with pancreatic neuroendocrine cancer (PNET) — the same disease that killed Apple’s founder and CEO Steve Jobs. After three years of progress…
The hemophilia B treatment Rebinyn is available in the United States, its maker Novo Nordisk reports. Rebinyn, which is administered intravenously, replaces the blood clotting factor IX that is missing in the disease. The U.S. Food and Drug Administration approved it in May 2017 to control bleeding episodes and manage bleeding…
Chris Bombardier has just made history by becoming the first person with hemophilia ever to scale the seven summits this January. Bombardier climbed each continent’s highest peak to raise awareness for hemophilia — and to show that with adequate training, medical assistance, preparation and willpower, even someone with a bleeding…
Catalyst Biosciences recently announced that top-line data from the Phase 1/2 trial of CB 2679d/ISU304 in patients with hemophilia B will be presented at the 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Feb. 7-9 in Madrid, Spain. The oral presentation, titled…
Clinical trials of Hemlibra (emicizumab-kxwh) continue to show significant reductions in bleeding episodes in patients with hemophilia A with inhibitors, Genentech recently announced. Data from Hemlibra’s clinical development program were presented at the 59th American Society of Hematology (ASH) Annual Meeting. The results show that in hemophilia A patients with inhibitors…
